CRC Sharpens Its Focus on California

LONG BEACH, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — California Resources Corporation (NYSE: CRC) today announced the signing of an agreement to divest its Uinta Basin assets to an undisclosed buyer for total cash consideration of approximately $90 million, subject to customary purchase price adjustments. The transaction further aligns CRC’s portfolio with its California operations and captures additional value from non-core assets acquired through the Berry merger. CRC expects to use the net proceeds for shareholder returns and other corporate purposes.

“Today’s transaction strengthens our business. The monetization of our Uinta Basin assets sharpens our focus on California and captures additional value from the Berry merger,” said Francisco Leon, CRC President and Chief Executive Officer. “This transaction enhances our capital allocation flexibility, allowing us to invest in higher-return opportunities within the Golden State and supports our shareholder return strategy. The sale also helps offset the purchase price of our recent midstream transaction.”

The transaction has an effective date of July 1, 2026. Closing is subject to the receipt of certain third-party consents and other customary conditions, and is expected by year end. Following the closing of the transaction, CRC expects to provide additional financial and operating guidance.

Advisor

RBC Capital Markets served as financial advisor to CRC.

About California Resources Corporation

California Resources Corporation (CRC) is an independent energy and carbon management company advancing the energy transition. CRC is committed to environmental stewardship while safely providing local, responsibly sourced energy. CRC is also focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing CCS and other emissions reducing projects. For more information about CRC, please visit crc.com.

Forward-Looking Statements

Information set forth in this communication, including financial estimates and statements as to the effects of the Berry merger and the Uinta divestiture, constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other securities laws. All statements other than historical facts are forward-looking statements, and include statements regarding the benefits of the Berry merger and the Uinta divestiture, CRC’s future financial position, business strategy, projected revenues, earnings, costs, capital expenditures and plans and objectives and intentions of management for the future. Words such as “expect,” “could,” “may,” “anticipate,” “intend,” “plan,” “ability,” “believe,” “seek,” “see,” “will,” “would,” “estimate,” “forecast,” “target,” “guidance,” “outlook,” “opportunity” or “strategy” or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements are based upon the current beliefs and expectations of the management of CRC and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, projected in, or implied by, such statements.

Although CRC believes the expectations and forecasts reflected in its forward-looking statements are reasonable, they are inherently subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond its control. No assurance can be given that such forward-looking statements will be correct or achieved or that the assumptions are accurate or will not change over time. Particular uncertainties that could cause CRC’s actual results to be materially different than those expressed in its forward-looking statements are described in its most recent Annual Report on Form 10-K and its other periodic filings with the SEC. These factors include, but are not limited to: fluctuations in commodity prices; production levels and/or pricing by OPEC, OPEC+ or U.S. producers; government policy, war and political conditions and events; integration efforts and projected synergies and other benefits in connection with the Berry merger, the Uinta divestiture and other acquisitions, divestitures and joint ventures; regulatory actions and changes that affect the oil and gas industry generally and us in particular; the efforts of activists to delay or prevent oil and gas activities or the development of CRC’s carbon management segment; changes in business strategy and the ability and financial resources to execute our capital plan in a timely manner; lower-than-expected production; changes to estimates of reserves and related future cash flows; the recoverability of resources and unexpected geologic conditions; general economic conditions and trends; results from operations and competition in the industries in which it operates; CRC’s ability to realize the anticipated benefits from prior or future efforts to reduce costs; environmental risks and liability; the benefits contemplated by its energy transition strategies and initiatives; CRC’s ability to successfully identify, develop and finance carbon capture and storage projects, power projects and other renewable energy efforts; future dividends and share repurchases and de-leveraging efforts; and natural disasters, accidents, mechanical failures, power outages, labor difficulties, cybersecurity breaches or attacks or other catastrophic events.

CRC cautions you not to place undue reliance on forward-looking statements contained in this document, which speak only as of the date hereof, and CRC is under no obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statements, whether as a result of new information, future events or otherwise. This communication may also contain information from third-party sources. This data may involve a number of assumptions and limitations, and CRC has not independently verified them and does not warrant the accuracy or completeness of such third-party information.

Contacts:

Daniel Juck (Investor Relations)
818-661-3700
CRC_IR@crc.com 
Hailey Bonus (Media)
714-874-7732
CRC.Communications@crc.com 

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies (NASDAQ: NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 outstanding shares of Series A Convertible Preferred Stock for $6 million in cash, with zero common shares issued in the process.

The move comes only days after NeOnc announced a $15 million registered direct offering, creating a notable one-two punch: fresh capital for the clinical-stage biotech while simultaneously eliminating a preferred security that could have converted into common stock at a substantial discount. The company said the financing was specifically structured to support the redemption.

“We made a deliberate decision to redeem the Series A Preferred Stock in cash and eliminate the potential dilution these securities represented for our shareholders,” CEO and Executive Chairman Amir F. Heshmatpour said.

The timing is particularly notable because the preferred stock’s conversion terms could have become more consequential. Issued in June for $5 million in gross proceeds, the Series A shares carried a four-month cash-redemption window. Had NeOnc not redeemed them, the stated value would have increased and holders could have elected to convert into common stock at 80% of the lowest closing price during the preceding five trading days, subject to a $1 floor.

Instead, NeOnc has effectively shut that door.

The company isn’t making the capital-structure cleanup in isolation. NeOnc is entering the next phase of its CNS cancer story with two clinical programs moving forward. NEO100 recently delivered topline Phase 2a results in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months.

Meanwhile, NEO212 has completed Phase 1 dose escalation, established a recommended Phase 2 dose of 610 mg, and received UAE IND authorization as NeOnc expands its international development pathway.

That puts the latest preferred-stock redemption into a larger narrative: NeOnc is attempting to simplify its capitalization while pushing its drug pipeline toward increasingly important clinical and regulatory milestones.

“We are focused on translating clinical progress into lasting value for patients and shareholders,” Heshmatpour said.

NEO100 and NEO212 remain investigational programs, but the capital-structure move is clear: NeOnc chose to eliminate a potential source of discounted-share conversion before it became available.

For investors watching NeOnc, the story is therefore shifting from simply raising money to how efficiently that capital can be deployed against an advancing CNS oncology pipeline, with one potentially dilutive security now off the table.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Multi-Service Award with a Financial Services Group in Asia Expands Primech’s Integrated Facility Services Portfolio

SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company”), a leading technology-driven facility services provider serving public and private sectors across Singapore, today announced that its subsidiary, Primech A & P Pte. Ltd. (“Primech A & P”), has secured a three-year integrated facility services contract with a financial services group in Asia, valued at approximately S$7.36 million (US$5.78 million).

Contract Details

Under the contract, Primech A & P will provide office cleaning, pest control and waste management services, bringing multiple essential facility requirements under an integrated service delivery model. Services under the contract are expected to commence in the second half of 2026.

The award demonstrates Primech A & P’s ability to deliver multi-service facility solutions for large-scale corporate environments and further expands the Company’s presence in the financial services sector.

The contract value is an estimate based on agreed scope and indicative service volumes, and actual revenue may vary based on usage and scope adjustments.

Advancing Primech’s Integrated Facility Services Model

The contract reflects Primech A & P’s continued expansion of its core cleaning capabilities through a broader integrated facility services model.

By combining office cleaning, pest control and waste management within a single engagement, Primech A & P will coordinate complementary facility services to support the day-to-day operational requirements of the client’s corporate environment.

The multi-service scope builds on Primech A & P’s established cleaning operations while broadening the range of facility services delivered to its customers. This approach enables the Company to address a wider range of operational requirements and deepen its engagement with major commercial and institutional customers.

The award also adds to Primech’s portfolio of multi-year contracts, providing recurring business visibility while supporting the Company’s continued expansion across key commercial sectors.

Management Commentary

“This contract represents an important addition to our commercial portfolio and demonstrates the breadth of services Primech A & P can deliver within a single engagement,” said Ken Ho, Chairman and Chief Executive Officer of Primech Holdings Limited.

“As customers increasingly look for reliable partners that can support multiple aspects of their facility operations, we see opportunities to build on our core cleaning capabilities by delivering a broader range of integrated services. This contract brings together office cleaning, pest control and waste management, demonstrating how we can support more of our customers’ facility requirements through a coordinated service model.”

About Primech Holdings Limited

Primech Holdings Limited (Nasdaq: PMEC) is a Singapore-headquartered, technology-driven facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the Group provides cleaning, facilities maintenance, stewarding, waste management and pest control services to public and private sector clients.

Through its subsidiary Primech AI, the Group develops HYTRON, an autonomous restroom-cleaning robot that combines AI perception with robotic manipulation. HYTRON has been commercially deployed in Singapore, with international expansion underway, including a distribution agreement in South Korea and market-entry activities in the United States. The Group also operates HomeHelpy, a digital home-services booking platform serving the consumer market.

Primech Holdings was incorporated in 2020 and listed on the Nasdaq Capital Market in October 2023. For more information, visit investor.primechholdings.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements about the value, duration, scope, and revenue recognition of the contract described in this announcement, and about anticipated revenues, growth, and expansion. Contract values are estimates based on agreed scope, pricing, and expected service volumes. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the SEC on July 29, 2026, and its other filings with the SEC.

Investor Relations

Primech Holdings Limited
ir@primechholdings.com
www.primechholdings.com

Opening General Session to Feature Leaders from Host Utility CenterPoint Energy and Pacific Gas & Electric, Duquesne Light Company, San Antonio Water System and Spire Energy

LIBERTY LAKE, Wash., Sept. 17, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), the infrastructure provider for modern energy and water management, revealed the speaker lineup for its premier customer-focused event, Itron Inspire 2026. The event will take place in Houston, TX, Oct. 16-21, 2026, with CenterPoint Energy serving as the host utility. More than 1,000 leaders from electric, water, natural gas and smart city organizations will gather to connect with peers and explore practical approaches for addressing the challenges shaping energy and water delivery.

“Every utility is navigating its own set of competing priorities. Demand is growing, infrastructure needs are mounting, workforces are stretched and affordability remains top of mind—all while customer expectations continue to rise,” said Marina Donovan, vice president of global marketing, ESG and public affairs. “These challenges can’t be solved by technology alone. Each year at Itron Inspire, the industry comes together to share what’s working, learn from one another and discuss how utilities can continue to meet the needs of the communities they serve.”

The main event, the Knowledge Conference, takes place Oct. 18-20 and features keynote presentations, breakout sessions and networking events. In the Knowledge Center, attendees can interact with Itron’s integrated solutions and partner offerings through live demonstrations and conversations with product experts. The Itron Experience will also return this year, giving attendees a chance to participate in a virtual game that simulates real-world utility scenarios. Participants will respond to evolving conditions, make trade-off decisions and compete against their peers to achieve the best outcomes.

Keynotes & General Sessions

Opening General Session | Monday, Oct. 19, 8:00-9:30 a.m.

  • Ed De Varona, senior vice president of CenterPoint Energy’s electric business, will discuss how the utility is navigating growth, embracing innovation and improving grid resiliency.
  • Tom Deitrich, president and CEO of Itron, will highlight the role of data, edge intelligence and AI in helping utilities turn operational insight into action. He’ll also be joined by Mike Delaney, vice president of strategy and innovation at Pacific Gas & Electric (PG&E), for a conversation on how the utility is applying intelligence at the edge to make home electrification easier, reduce operational and maintenance costs and strengthen the utility’s ability to detect and predict grid conditions.
  • Marina Donovan, vice president of global marketing, ESG and public affairs, will discuss findings from the 2026 Itron Resourcefulness Report and host a panel discussion with Matthew Llewellyn, director of field operations, customer experience at San Antonio Water System; Brad Anderson, manager, meter reading technologies at Spire; and Mitch Davda, director, meter operations at Duquesne Light Company. Together, they’ll examine how utilities are embracing edge intelligence to optimize operations, improve safety and strengthen reliability and resiliency using infrastructure already in place.

Tuesday General Session | Tuesday, Oct. 20, 8:00-9:30 a.m.

  • During the Tuesday General session, Sunny Wescott, Federal Emergency Response Chief Meteorologist and Executive Director for the Geospatial Intelligence Information Sharing and Analysis Center, will discuss how extreme weather is reshaping risk for utilities across the nation.

Big Picture Sessions

  • Resiliency Solutions: Planning Smarter, Responding Faster and Operating Safer | Monday, Oct. 19, 2:15-3:15 p.m.: Matt Crye and Danny Petrecca, vice presidents of Resiliency Solutions at Itron, will introduce Itron’s new Resiliency Solutions business unit and its focus on worker safety, damage prevention, emergency preparedness and digital construction management. The session will continue with a discussion moderated by Dr. Michael Webber, energy-water nexus expert and professor at The University of Texas at Austin, featuring Crye and Petrecca as well as Monica Karuturi, executive vice president and general counsel at CenterPoint Energy, and Emeka Igwilo, Chief Data Offer at Southern Company Gas, on how these solutions are being applied in the field.
  • Modernize, Don’t Just Replace: Unlocking Grid Edge Value | Tuesday, Oct. 20, 11:15 a.m. -12:00 p.m.: Matt Wakefield, director of information, communication & cyber security at EPRI will moderate a panel with Chris Moris, chief grid architect at PG&E; Robert Trask, principal engineer at Salt River Project; and Akilan Kapilan, director industry advisor at Microsoft, about practical approaches for maximizing existing AMI investments. The group will discuss strategies for modernizing infrastructure, prioritizing high-value applications and turning AMI data into meaningful operational outcomes.

Women Who Inspire | Tuesday, Oct. 20, 3:15-4:15 p.m.

The Women Who Inspire session returns this year in a new format, bringing attendees together for an afternoon tea social and panel discussion featuring women leaders from across the energy and water industries. Katrina Polk, vice president of product management at Itron, will moderate a discussion with Elvimar Rivas, senior analyst at Con Edison; Shelley Parker, vice president at Alectra Utilities; and Latisha Hill, vice president of community affairs and chief customer officer at Avista. Panelists will share insights from their personal and professional journeys, discussing topics such as navigating industry change, embracing innovation and mentorship.

Breakout Sessions

More than 75 customer- and partner-led breakout sessions will take place throughout the conference. Led by utility and industry experts, the sessions are organized across five tracks: Applications, Outcomes and Services; Data Management; Mobile and Measurement Solutions; Multi-Purpose Network Solutions; and Resiliency Solutions. Sessions will showcase how organizations are using intelligence and data-driven strategies to modernize existing infrastructure, respond faster to disruption, manage rising demand and improve outcomes for customers and communities.

Additional Learning Opportunities

Customer forums and working groups, included with a full conference pass, will take place on Sunday, Oct. 18 and Wednesday, Oct. 21, and provide attendees with opportunities to engage directly with product teams, collaborate with industry peers and learn about topics in greater depth. These interactive sessions are designed to foster meaningful dialogue, knowledge sharing and valuable feedback that helps shape the evolution of energy and water solutions. A complete list of sessions can be found here.

Additionally, Itron Inspire features pre-conference product training opportunities from Friday, Oct. 16 to Sunday, Oct. 18 for products including OpenWay® Collection Manager, Temetra® and MV-90™ xi. From one-day introductory courses to three-day certified training sessions, the hands-on, expert-led trainings allow utilities to maximize their professional development. For additional information and to register for pre-conference trainings, click here.

For more information about Itron Inspire 2026, visit www.itron.com/inspire. Join the conversation on social media using #ItronInspire26.

About Itron

Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com.

Itron®, OpenWay, Temetra, and the Itron Logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

For additional information, contact:

Itron, Inc.

Alison Mallahan
Senior Manager, Corporate Communications
509-891-3802
PR@Itron.com

Paul Vincent
Vice President, Investor Relations
512-560-1172
Investors@itron.com

Itron, Inc.

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics

Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the appointment of Robert J. Spiegel, M.D., FACP, to its Board of Directors.

Dr. Spiegel is an accomplished physician, biopharmaceutical executive and drug developer with decades of experience spanning oncology, clinical development, regulatory strategy and pharmaceutical leadership. He spent over 25 years at Schering-Plough Research Institute, where he held increasingly senior positions culminating in his role as Chief Medical Officer from 1998 to 2009. He later served as Chief Medical Officer of PTC Therapeutics from 2014 to 2016 and is currently Founder and Principal of Spiegel Consulting LLC and Associate Professor of Medicine at Weill Cornell Medical College.

“We are pleased to welcome Dr. Spiegel to Ernexa’s Board of Directors at an important stage in the Company’s development,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “Dr. Spiegel brings an exceptional combination of oncology expertise, clinical development leadership and regulatory experience. His perspective will be highly valuable as we continue advancing ERNA-101 toward clinical evaluation and work to translate our encouraging preclinical findings into a potential new therapeutic option for patients with ovarian cancer and other difficult-to-treat malignancies.”

Dr. James Bristol, Chairman of the Board, added, “Dr. Spiegel’s extensive oncology drug development and regulatory experience will bring valuable perspective to Ernexa’s Board as we prepare ERNA-101 for clinical evaluation. We look forward to working with him as the Company advances its development strategy and builds long-term value for patients and shareholders.”

During his tenure at Schering-Plough, Dr. Spiegel played a significant role in the clinical development and regulatory approval of numerous therapies. His experience included advancing alpha-interferon through Phase 1 to Phase 3 development and FDA approval, developing temozolomide from Phase 1 through worldwide regulatory approval for glioblastoma, and contributing to development programs across oncology, immunology and other therapeutic areas. As Chief Medical Officer, he participated in research governance spanning first-in-human, proof-of-concept and registration-stage development decisions and was involved in more than 30 successful New Drug Applications.

Dr. Spiegel also brings extensive public company board experience, having served on the boards of numerous biotechnology and pharmaceutical companies throughout his career. He currently serves on the boards of Geron Corporation, Ayala Pharmaceuticals, RenovoRx and Sun Pharma Advanced Research Corporation (SPARC).

“I am excited to join Ernexa’s Board of Directors as the Company works to advance its innovative cell therapy platform toward the clinic,” said Dr. Spiegel. “ERNA-101 represents a compelling approach to addressing some of the persistent challenges in ovarian cancer, and I look forward to working with Sanjeev, my fellow Board members and the broader Ernexa team as the Company continues preparing the program for clinical development and explores its potential across oncology.”

Dr. Spiegel earned his M.D. from the University of Pennsylvania and his B.A., cum laude, from Yale University. He completed his medical oncology fellowship at the National Cancer Institute at the National Institutes of Health and currently serves as an Associate Professor of Medicine at Weill Cornell Medical College.

Advancing ERNA-101 Toward Clinical Development

ERNA-101 is Ernexa’s lead cell therapy candidate and is designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The Company’s initial development focus is ovarian cancer, where significant unmet need remains for new therapeutic approaches capable of generating durable responses.

Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). The Company’s allogeneic synthetic iMSCs are designed to provide a scalable, off-the-shelf treatment approach without the need for patient-specific cell harvesting.

Ernexa continues to advance ERNA-101 toward clinical evaluation while executing the manufacturing, regulatory and clinical activities necessary to support its planned transition into a clinical-stage biotechnology company.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Sanoma Corporation, Stock Exchange Release, 17 September 2026 at 3:40 p.m. EET

Change in the composition of Sanoma’s Shareholders’ Nomination Committee

The composition of the Shareholders’ Nomination Committee of Sanoma Corporation has changed. Robin Langenskiöld and Rafaela Seppälä have stepped down from the Nomination Committee following the transfer of their entire shareholding in Sanoma to RR & Co Ab on 9 September 2026.

In accordance with the charter of the Nomination Committee, the next largest shareholders of Sanoma as of 31 May 2026, Varma Mutual Pension Insurance Company and Ilmarinen Mutual Pension Insurance Company, are entitled to appoint representatives to the Nomination Committee. In addition, in accordance with its charter, the Nomination Committee has invited RR & Co Ab, which became the third largest shareholder in Sanoma after the share transfer on 9 September 2026, to appoint an additional member to the Nomination Committee for the rest of its term.

The new composition of Sanoma Corporation’s Shareholders’ Nomination Committee is as follows:

  • Juhani Mäkinen, Vice Chair of the Board, Jane and Aatos Erkko Foundation
  • Antti Herlin, Chair of the Board, Holding Manutas
  • Hanna Kaskela, SVP, Sustainability and Communications, Varma Mutual Pension Insurance Company
  • Annika Ekman, EVP, Investments, Ilmarinen Mutual Pension Insurance Company
  • Lorna Bernardin-Aubouin, Board member, RR & Co Ab

Juhani Mäkinen will continue as the Chair of the Nomination Committee and Timo Lappalainen, Chair of Sanoma’s Board of Directors, continues to serve as an expert in the Nomination Committee.

The purpose of the Shareholders’ Nomination Committee is to prepare the proposals on the number, composition and remuneration of the members of the Board of Directors to the Annual General Meeting. The items proposed by the Shareholders’ Nomination Committee will be presented in a separate Stock Exchange Release as well as in the notice to the 2027 Annual General Meeting.

Additional information
Kaisa Uurasmaa, Head of Investor Relations and Sustainability, tel. +358 40 560 5601

Sanoma 

Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Across Europe, we support teachers and students with the best-in-class learning content and solutions to help all students reach their potential. We combine pedagogical expertise with quality content and innovative educational technologies to help shape the future of K12 education.

Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners.

We have a clear organic growth pathway in K12 education and aim to accelerate growth through value-creating M&A. Across our business, we are responsibly harnessing the opportunities of AI, always emphasising human oversight. Our Sustainability Strategy is designed to maximise our positive ‘brainprint’ on society and to minimise our environmental footprint. We are committed to the UN Sustainable Development Goals and signatory to the UN Global Compact.

Today, we operate across Europe and employ close to 5,000 professionals. In 2025, our net sales amounted to approx. 1.3bn€ and our adjusted operating profit margin was 14.4%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at sanoma.com.

Multi-year strategic agreement increases capacity for high-performance SiGe technology to support growing AI infrastructure demand

MALTA, N.Y., Sept. 17, 2026 (GLOBE NEWSWIRE) — GlobalFoundries (Nasdaq: GFS) (GF) and Marvell Technology, Inc. (Nasdaq: MRVL), a leader in data infrastructure semiconductor solutions, today announced an expanded multi-year agreement to increase capacity for GF’s silicon germanium (SiGe) technology at its Burlington, Vermont, facility to support growing demand for next-generation optical connectivity.

Modern AI data centers operate as distributed compute systems, where performance depends not only on accelerators, but also on the high-speed interconnects that move data between them. As AI systems scale, moving data efficiently is becoming increasingly critical to overall performance. The expanded collaboration between GF and Marvell will increase capacity for high-performance SiGe technology used in next-generation pluggable optical transceivers, Near-Packaged Optics (NPO) and Co-packaged Optics (CPO).

The expanded agreement builds on existing production and is expected to add significant capacity to support Marvell’s growing requirements.

GF’s SiGe technology portfolio provides the high-frequency performance, signal integrity and power efficiency required for advanced optical networking applications. Its current technology supports 200G-per-lane optical connectivity, with a roadmap designed to address higher-speed generations as AI and cloud data center bandwidth requirements continue to grow. GF has manufactured advanced SiGe technology for over a decade and continues to co-integrate SiGe, silicon photonics and advanced packaging for new optical connectivity architectures including NPO and CPO.

“AI is fundamentally changing the way data centers are built, and connectivity is becoming increasingly critical to unlocking the performance of these systems,” said Robb Johnson, Vice President, Foundry Technology, Marvell. “As the industry moves toward higher-bandwidth optical architectures, including NPO and CPO, Marvell is investing aggressively to lead this transition. Our expanded collaboration with GF will help ensure we have the SiGe technology and manufacturing capacity to support the significant growth we see ahead.”

“SiGe is where GF’s decades of high-performance radio frequency and analog leadership translate directly into breakthrough optical performance,” said Shankaran Janardhanan, senior vice president of Photonics & RF businesses at GF. “This agreement reinforces our long-standing relationship with Marvell and reflects the critical role SiGe technology plays in enabling high-speed optical networking for AI infrastructure. We will continue investing in our technology roadmap and manufacturing capabilities both in the U.S. and around the world to support our customers’ future growth.”

The agreement builds on more than a decade of collaboration between GF and Marvell and reflects the increasingly important role optical networking technologies play in enabling AI and cloud infrastructure at scale.

About GF
GlobalFoundries (GF) is a leading manufacturer of essential semiconductors, enabling AI at scale from the cloud to the physical world. Through deep partnerships with customers, GF delivers differentiated, power-efficient and high-performance solutions for automotive, aerospace and defense, data center, smart mobile devices, internet of things and other high-growth markets. With global manufacturing operations across the U.S., Europe and Asia, GF is a trusted and holistic technology partner for customers around the world. GF’s talented, global team remains focused every day on security, longevity and sustainability. For more information, visit www.gf.com.

Forward-looking information
This news release may contain forward-looking statements, which involve risks and uncertainties. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. GF undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Media Contact:
Erica McGill
erica.mcgill@gf.com

  • EXELCO DIAMOND and GINZA DIAMOND SHIRAISHI Flagship Seoul Store Opened on August 27, 2026
  • New Seoul location in Yongsan-gu unites fine jewelry and contemporary art, marking the Japanese bridal jewelry group’s first entry into the South Korean market

NEW ART HOLDINGS Co., Ltd.

The showroom of the Seoul Flagship, featuring works by Korean artist Soonik Kwon. (Photo: NEW ART HOLDINGS Co., Ltd.)

NEW ART HOLDINGS Co., Ltd.

The showroom of the Seoul Flagship, featuring works by Korean artist Soonik Kwon. (Photo: NEW ART HOLDINGS Co., Ltd.)

TOKYO, Sept. 17, 2026 (GLOBE NEWSWIRE) — NEW ART HOLDINGS Co., Ltd. (TSE Standard Market: 7638) (“NEW ART” or the “Company”), a leading Japanese bridal jewelry group operating the EXELCO DIAMOND and GINZA DIAMOND SHIRAISHI brands, today announced the grand opening of its first store in South Korea — home to the EXELCO DIAMOND Seoul Flagship and the GINZA DIAMOND SHIRAISHI Seoul Flagship — which opened on August 27, 2026, at 70 Sowol-ro, Yongsan-gu in central Seoul, close to the Seoul Station transportation hub.

The store is operated by NEW ART KOREA Co., Ltd., a wholly owned Korean subsidiary of the Company.

Spanning 459.7 square meters (approximately 4,948 square feet), the new location is housed in White Stone Gallery, a space designed by the world-renowned architect Kengo Kuma. Conceived around the theme of “Art × Diamond × Jewelry,” the store presents both brands in a setting that integrates Korean contemporary art with two distinct heritage identities: EXELCO DIAMOND, rooted in the royal and aristocratic traditions of Europe, and GINZA DIAMOND SHIRAISHI, which has embodied Japanese bridal craftsmanship since 1994.

NEW ART HOLDINGS Co., Ltd.

GINZA DIAMOND SHIRAISHI (left) and EXELCO DIAMOND (right). (Image: NEW ART HOLDINGS Co., Ltd.)

The result is a new retail concept in which the worlds of these two brands converge under one roof, offering visitors an experience that goes beyond the selection of a ring. The store also features works by Soonik Kwon, one of Korea’s most celebrated contemporary artists. In a space where jewelry and art come together, the Seoul Flagship aims to deliver a destination that earns the lasting trust and loyalty of customers from Korea and beyond.

NEW ART HOLDINGS Co., Ltd.

The salon of the Seoul Flagship, housed in White Stone Gallery, designed by architect Kengo Kuma. (Photo: NEW ART HOLDINGS Co., Ltd.)

NEW ART HOLDINGS Co., Ltd.

The salon of the Seoul Flagship, housed in White Stone Gallery, designed by architect Kengo Kuma. (Photo: NEW ART HOLDINGS Co., Ltd.)

The NEW ART Group will continue to invest in building the international presence of its brands and expanding its share of the global bridal jewelry market.

“Beautiful things enrich our lives and make life shine more brightly. With our first store in Seoul, we want to create exactly that kind of moment — a place where diamonds, jewelry, and art come alive together,” said Yukio Shiraishi, Representative Director and Chairman of NEW ART HOLDINGS. “This grand opening marks a new chapter for the Company. From Korea, we look forward to sharing our vision with customers on a global scale.”

“Korea is a natural next step in our expansion across Asia, and another milestone in building the international presence of our brands,” said Chen Szu Pei, Director of NEW ART Taiwan and Head of Web & Marketing. “In Seoul, as in Taiwan, Hong Kong, and Singapore, our focus is the same: bringing the customer experience we have refined in Japan — made-to-order craftsmanship and service that earns lifelong trust — to couples in each new market.”

About NEW ART HOLDINGS Co., Ltd.

Founded in September 1994 and headquartered in Ginza, Tokyo, NEW ART HOLDINGS Co., Ltd. (TSE Standard Market: 7638) is Japan’s leading specialist in bridal diamond jewelry, guided by the philosophy: “We harness the transformative power of art to inspire beauty, health, and happiness.” The Group operates a diversified portfolio spanning bridal jewelry, fine art, auction services, health & beauty, the food business in Hong Kong, and apparel across 17 consolidated subsidiaries — nine domestic and eight international.

The Group’s flagship jewelry brands, GINZA DIAMOND SHIRAISHI and EXELCO DIAMOND, operate 154 stores globally — 128 across Japan and 26 internationally, spanning Taiwan, Hong Kong, Singapore and South Korea.

For more information, please visit: www.newart-ir.jp

Japan Media Contact

NEW ART HOLDINGS Co., Ltd.

IR Email: ir_inquiry@newart-global.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/b29a6ab1-2fea-4a96-8f85-967e96dde994

https://www.globenewswire.com/NewsRoom/AttachmentNg/238b06a9-4073-4fc1-aeb7-b6bc7615b50d

https://www.globenewswire.com/NewsRoom/AttachmentNg/a4a1aa0f-03cf-40df-9754-5c90d867ee91

https://www.globenewswire.com/NewsRoom/AttachmentNg/4bcff0e6-fef0-478d-86f7-c021f88edd45

https://www.globenewswire.com/NewsRoom/AttachmentNg/2d1e286a-ad2d-41ca-a428-f67ed250c74c

Separation Would Create Two High-Quality Public Companies, Each With Distinct Growth Strategies and Long-Term Value Creation Opportunities

  • National Fuel’s Integrated Upstream and Gathering business would become an independent public company focused solely on its highly integrated, Appalachian upstream and gathering natural gas business.
  • Post-separation, National Fuel would be a 100% rate-regulated company with natural gas utility and interstate pipeline and storage assets across Pennsylvania, Ohio, and New York.
  • The separation would be effected through a tax-free distribution of shares to National Fuel shareholders.
  • National Fuel expects to conclude its evaluation by October 15, 2026.

WILLIAMSVILLE, N.Y., Sept. 17, 2026 (GLOBE NEWSWIRE) — National Fuel Gas Company (NYSE: NFG) (“National Fuel” or the “Company”) announced that by October 15, 2026 its Board of Directors intends to complete an ongoing evaluation of a plan to separate the Company into two independent publicly traded companies, which remains subject to final Board approval.

If pursued and upon completion of the transaction, National Fuel shareholders would own shares in both National Fuel and its Integrated Upstream and Gathering (“IUG”) business, creating two focused companies, each with significant scale, strong financial profiles, and distinct growth opportunities. As independent entities, each publicly traded company would be well positioned to deliver long-term growth and sustainable value creation for investors, customers, and employees, with the standalone businesses expected to benefit from:

  • Greater capital allocation flexibility to pursue each company’s distinct growth opportunities and shareholder return priorities, supported by highly experienced leadership teams, strong balance sheets, and more tailored capital structures.
  • Preserving the key benefits of integration that each business realizes today, including the capital efficiencies provided by IUG’s integrated upstream and gathering operations, and critical operating synergies that support customer affordability and commercial benefits across National Fuel’s regulated businesses.
  • Potentially more compelling equity stories that increase visibility among relevant investors and research analysts and align each public company with its natural investor base.

“National Fuel has benefitted for many years from the strength and diversification of our integrated business model, which provided the financial capacity and cash flow generation to support significant strategic investments across the Company, including multiple transformative acquisitions since 2020,” said David P. Bauer, President and Chief Executive Officer of National Fuel. “Over that same period, the capital markets and operating environment of our regulated and non-regulated natural gas businesses have evolved meaningfully. With the expected closing of our Ohio gas utility acquisition next month, each business will be a scaled platform with distinct strategic priorities, organic growth opportunities, capital needs, and investment profiles.”

If approved, National Fuel would separate IUG through a distribution of shares of IUG to National Fuel shareholders in a manner which would be intended to be tax-free for National Fuel and its shareholders for U.S. federal income tax purposes.

National Fuel: 100% regulated natural gas platform, with a highly-strategic, growing integrated utility and interstate pipeline and storage assets in constructive regulatory jurisdictions

If a separation is pursued, National Fuel would be a fully-regulated natural gas business with nearly $5 billion of rate base.1 Its utility business would serve 1.1 million customers across Ohio, New York and Pennsylvania. In addition, the FERC-regulated pipeline and storage business would provide nearly 5 Bcf per day of contracted natural gas transportation capacity and 77 Bcf of fully-contracted natural gas storage services.

National Fuel operates across constructive regulatory jurisdictions, with significant long-term investment opportunities, supported by ongoing infrastructure modernization programs and increased natural gas demand accelerating the need for new pipeline and storage infrastructure. Together, these dynamics support continued investment in existing pipeline systems, as well as the ongoing execution of transmission and storage expansions to support growing demand.

National Fuel would benefit from a strong balance sheet and investment grade credit metrics expected to be in line with some of the strongest in the utility sector, with no need to raise incremental equity capital expected over the next five years based on current capital plans. This could potentially provide the company with significant financial flexibility to fund its growth plans and position it to execute on its long-term growth opportunities.

Integrated Upstream and Gathering: A premier, integrated Appalachian natural gas business with high-quality assets, and best-in-class inventory depth and capital efficiency trends

If a separation is pursued, IUG will be a leading integrated, low-cost, upstream natural gas business, with approximately 1.2 million total net acres in Appalachia and approximately 1.1 Bcf per day of net natural gas production. IUG owns significant integrated gathering assets that transport the vast majority of its production, providing greater operational control, cost certainty, and alignment across its operating footprint. With approximately 5 Tcf of natural gas reserves and more than 40 years of prospective Marcellus and Utica development inventory, IUG would be well positioned to grow production, extend its track record of operational improvement, and create long-term value through disciplined capital allocation.

Since transitioning its development program to the Eastern Development Area in 2023, IUG has delivered industry-leading capital efficiency improvements of approximately 25%, enabling IUG to generate increased production and free cash flow per dollar invested while enhancing potential shareholder returns. Combined with its integrated gathering platform and portfolio of firm transportation capacity that provides access to premium markets, IUG would be expected to maintain a best-in-class operating cost structure and market access advantages that support long-term value creation.

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor to National Fuel, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel.

About National Fuel Gas Company
National Fuel is a diversified energy company headquartered in Western New York that currently operates an integrated collection of natural gas assets across three operating segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. Additional information about National Fuel is available at www.nationalfuel.com.

Cautionary Statements
Certain statements contained herein, including statements identified by the use of the words “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “guidance,” “intends,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “targets,” “will,” “would”, and variations of such words and similar future or conditional expressions, and statements which are other than statements of historical facts, are intended to identify “forward-looking statements” as defined under U.S. federal securities laws, including, but not limited to, statements, estimates, and projections relating to the potential separation of the Company into two companies (the “Separation”), including the timing and structure of the Separation, the characteristics of the separated businesses, and the expected benefits of the Separation, future operating and financial performance and long-term strategy, and the assumptions underlying such expected benefits, targets, strategies, and statements. These forward-looking statements are based on management’s beliefs, expectations, estimates, and projections at the time they are made and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs, and projections contained herein are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that such expectations, beliefs, or projections will result or be achieved or accomplished. There can be no guarantees with respect to whether the Separation will be completed. In addition to other factors, the following are among the important factors that could cause actual results to differ materially from those discussed in the forward-looking statements: the ability to effect the Separation and to meet the conditions related thereto; the ability to obtain any consents or approvals required to complete the Separation; the ability of the separated companies to each succeed as standalone publicly traded companies; negative effects of the announcement or pendency of the Separation on the market price of the Company’s securities and/or on the Company’s financial performance; the possibility that the Separation will not achieve its intended benefits; the possibility of disruption, including disputes, litigation, or unanticipated costs in connection with the Separation; the impact of the Separation on the Company’s businesses and the risk that the Separation may be more difficult, time-consuming, or costly than expected, including the impact on the Company’s resources, systems, procedures, and controls, diversion of management’s attention, and the impact and possible disruption of existing relationships with regulators, customers, suppliers, employees, and other business counterparties; the ability to achieve anticipated capital structures in connection with the Separation; the ability to achieve anticipated credit ratings in connection with the Separation; the ability to achieve anticipated tax treatments in connection with the Separation and future, if any, divestitures, mergers, acquisitions, and other portfolio changes, and the impact of changes in relevant tax and other laws and regulations; changes in laws, regulations, or judicial interpretations to which the Company is subject, including those involving derivatives, taxes, safety, employment, climate change, other environmental matters, real property, and exploration and production activities such as hydraulic fracturing; governmental/regulatory actions, initiatives, and proceedings, including those involving rate cases (which address, among other things, target rates of return, rate design, retained natural gas, and system modernization), environmental/safety requirements, affiliate relationships, industry structure, and franchise renewal; changes in economic conditions, including the imposition of additional tariffs on U.S. imports and related retaliatory tariffs, inflationary pressures, supply chain issues, liquidity challenges, and global, national, or regional recessions, and their effect on the demand for, and customers’ ability to pay for, the Company’s products and services; the Company’s ability to complete strategic transactions, and to recognize the anticipated benefits of such transactions; governmental/regulatory actions and/or market pressures to reduce or eliminate reliance on natural gas; the Company’s ability to estimate accurately the time and resources necessary to meet emissions targets; changes in the price of natural gas; impairments under the SEC’s full cost ceiling test for natural gas reserves; the creditworthiness or performance of the Company’s key suppliers, customers, and counterparties; financial and economic conditions, including the availability of credit, and occurrences affecting the Company’s ability to obtain financing on acceptable terms for working capital, capital expenditures, other investments, and acquisitions, including any downgrades in the Company’s credit ratings and changes in interest rates and other capital market conditions; negotiations with the collective bargaining units representing the Company’s workforce, including potential work stoppages during negotiations; changes in price differentials between similar quantities of natural gas sold at different geographic locations, and the effect of such changes on commodity production, revenues, and demand for pipeline transportation capacity to or from such locations; the impact of information technology disruptions, cybersecurity, or data security breaches, including the impact of issues that may arise from the use of artificial intelligence technologies; factors affecting the Company’s ability to successfully identify, drill for, and produce economically viable natural gas reserves, including, among others, geology, lease availability and costs, title disputes, weather conditions, water availability and disposal or recycling opportunities of used water, shortages, delays, or unavailability of equipment and services required in drilling operations, insufficient gathering, processing, and transportation capacity, the need to obtain governmental approvals and permits, and compliance with environmental laws and regulations; increased costs, delays, or changes in plans with respect to Company projects or related projects of other companies, as well as difficulties or delays in obtaining necessary governmental approvals, permits or orders or in obtaining the cooperation of interconnecting facility operators; increasing health care costs and the resulting effect on health insurance premiums and on the obligation to provide other post-retirement benefits; other changes in price differentials between similar quantities of natural gas having different quality, heating value, hydrocarbon mix or delivery date; the cost and effects of legal and administrative claims against the Company or activist shareholder campaigns to effect changes at the Company; uncertainty of natural gas reserve estimates; significant differences between the Company’s projected and actual production levels for natural gas; changes in demographic patterns and weather conditions, including those related to climate change; changes in the availability, price, or accounting treatment of derivative financial instruments; changes in laws, actuarial assumptions, the interest rate environment, and the return on plan/trust assets related to the Company’s pension and other post-retirement benefits, which can affect future funding obligations and costs and plan liabilities; economic disruptions or uninsured losses resulting from major accidents, fires, severe weather, natural disasters, terrorist activities, or acts of war, as well as economic and operational disruptions due to third-party outages; significant differences between the Company’s projected and actual capital expenditures and operating expenses; increasing costs of insurance, changes in coverage, and the ability to obtain insurance; other factors described in the risk factors set forth in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 10-K and subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, and disclaims any duty, to update, revise, or withdraw any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.

1 Projected as of December 31, 2026 and assumes the October 1, 2026 closing of National Fuel’s previously announced acquisition of CenterPoint’s Ohio natural gas utility business.

Analyst Contact: Ryan Vossler | 716-857-7158
Media Contact: Karen Merkel | 716-857-7654

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).

The findings extend the scientific understanding of Telomir-Zn beyond oncology, providing new evidence that modulation of intracellular metal homeostasis may influence disease-associated pathways across substantially different biological settings. In the AMD model, Telomir-Zn improved visual performance and retinal structure and was associated with restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward the profile observed in healthy animals.

Complementary mechanistic studies showed that Telomir-Zn reduced intracellular labile iron and potently inhibited iron-dependent Jumonji C histone demethylases (KDMs), enzymes that help regulate which genes cells turn on or off. The findings provide a potential mechanistic link between Telomir-Zn’s effects on intracellular metals and its emerging role in epigenetic regulation. In retinal degeneration, this biology may be particularly relevant to cellular programs involved in inflammation, senescence, DNA repair, and survival as retinal cells respond to oxidative and mitochondrial stress.

Telomir’s clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer (TNBC). The new retinal findings add to a growing body of published research supporting a common upstream biology centered on intracellular metal homeostasis and epigenetic regulation, while demonstrating that the biological relevance of Telomir-Zn may extend beyond the Company’s current clinical development focus.

The manuscript, titled “Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age-Related Retinal Degeneration,” was published in International Journal of Molecular Sciences. 2026, 27(18), 8265; DOI: 10.3390/ijms27188265.

Publication Highlights

Improved Visual Function and Reduced Retinal Degeneration

Untreated animals in the accelerated retinal degeneration model exhibited profound visual impairment, photoreceptor loss, retinal pigment epithelium disruption, and degeneration of multiple retinal layers.

After 14 days of oral treatment, Telomir-Zn significantly improved central visual response, moving-object tracking, and adaptation to changes in light intensity. Histological analysis demonstrated significant improvement in retinal degeneration, with restoration of thickness across multiple retinal layers, including the outer and inner nuclear layers, outer plexiform layer, and ganglion cell layer.

Reduced Mitochondrial Oxidative Stress and Protected Human Retinal Cells

The AMD model exhibited markedly elevated oxidative stress associated with mitochondrial dysfunction. Telomir-Zn significantly reduced brain reactive oxygen species, used in the study as a surrogate measure of mitochondrial oxidative stress, with the higher dose restoring values toward wild-type baseline.

In complementary experiments using human ARPE-19 retinal pigment epithelial cells, Telomir-Zn dose-dependently attenuated iron- and copper-induced calcium dysregulation and reduced copper-induced intracellular reactive oxygen species toward baseline.

Together, these findings demonstrate activity across two biologically relevant settings: reduction of mitochondrial oxidative stress in vivo and protection against metal-induced oxidative and calcium stress in human retinal cells. This is particularly relevant because oxidative stress, mitochondrial dysfunction, and metal dysregulation are central features of the retinal degeneration biology examined in the study.

Epigenetic and Telomere-Associated Changes

Telomeres are protective DNA sequences at the ends of chromosomes that are closely associated with cellular aging and genomic stability. In the accelerated retinal degeneration model, relative telomeric DNA content was significantly reduced compared with healthy wild-type animals, consistent with the model’s accelerated degenerative state.

Following Telomir-Zn treatment, relative telomeric DNA content increased dose-dependently toward the healthier profile observed in wild-type animals. Treatment was also associated with restoration of altered DNA methylation patterns at selected aging-associated CpG loci.

Together, these findings suggest that Telomir-Zn’s biological activity may extend beyond reducing oxidative stress to broader genomic and epigenetic processes associated with cellular aging and degeneration.

A Common Metal-Dependent Epigenetic Biology

Separate cellular studies described in the manuscript demonstrated that Telomir-Zn increased intracellular zinc while reducing labile Fe²⁺. Biochemical assays also demonstrated potent inhibition of multiple Fe²⁺-dependent Jumonji C histone demethylases across the KDM2, KDM5, and KDM6 families, with the strongest activity observed against KDM5B at an IC50 of 63 nM.

Most KDMs are iron-dependent enzymes that help regulate which genes cells turn on or off through changes in histone methylation. These enzymes influence cellular programs involved in inflammation, senescence, DNA repair, and cell survival. Because the KDMs evaluated in the study require Fe²⁺ for catalytic activity, reducing labile intracellular Fe²⁺ provides a potential upstream mechanism through which Telomir-Zn may influence disease-associated epigenetic programs.

In retinal degeneration, this may be particularly relevant because oxidative and mitochondrial stress can alter cellular programs governing inflammation, senescence, DNA repair, and survival. By changing the intracellular metal environment and inhibiting iron-dependent epigenetic enzymes, Telomir-Zn may help shift stressed cells toward a more protective epigenetic state.

The findings build upon Telomir-Zn’s previously published oncology research, where intracellular labile iron reduction and inhibition of iron-dependent KDMs were associated with epigenetic reprogramming and anti-tumor activity. In TNBC cells, iron-rescue experiments showed that adding iron back significantly reversed Telomir-Zn’s anti-cancer effect, directly linking iron availability to the compound’s activity.

Together, the published findings support an emerging biological framework in which Telomir-Zn modulates the intracellular metal environment to influence epigenetic machinery and downstream disease-associated cellular programs. The biological consequences may differ by disease—potentially disrupting pathways supporting tumor growth and survival in cancer while contributing to a more protective cellular environment under conditions of oxidative and mitochondrial stress in retinal degeneration.

This common metal-dependent epigenetic biology provides a potential explanation for why Telomir-Zn has demonstrated biological activity across substantially different preclinical disease settings, while the Company remains focused on advancing its clinical development program in oncology.

Management Commentary

“This study gives us an important new view of the relationship between intracellular metal balance, oxidative stress, epigenetic regulation and retinal degeneration,” said Dr. Itzchak Angel, Chief Scientific Advisor of Telomir. “Telomir-Zn significantly improved visual function, reduced retinal degeneration, and restored key retinal-layer thicknesses, supporting the potential relevance in a devastating disease such as AMD, beyond oncology.”

“Our clinical priority remains oncology, beginning with our FDA-cleared Phase 1/2 program in TNBC, but we believe the potential opportunity for Telomir-Zn could extend well beyond a single indication,” said Erez Aminov, CEO of Telomir. “As we build evidence across different disease models, we are seeing a common biology centered on intracellular metal homeostasis and epigenetic regulation. We believe this creates meaningful platform potential for Telomir-Zn across additional cancers and, over time, other diseases where this biology may play an important role.”

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.